Cargando…
Corrigendum: Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma
Autores principales: | Liu, Hailiang, Xu, Yong, Liang, Kai, Liu, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728366/ https://www.ncbi.nlm.nih.gov/pubmed/35004334 http://dx.doi.org/10.3389/fonc.2021.817747 |
Ejemplares similares
-
Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma
por: Liu, Hailiang, et al.
Publicado: (2020) -
Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021) -
Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2023) -
Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes
por: Liu, Rong, et al.
Publicado: (2021) -
Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma
por: Malvi, Parmanand, et al.
Publicado: (2022)